160 related articles for article (PubMed ID: 34572795)
1. Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Lee JS; Sinn DH; Park SY; Shin HJ; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Oh JH; Lee JI; Kim SU
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572795
[TBL] [Abstract][Full Text] [Related]
2. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis.
Shin SH; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
Liver Int; 2015 Mar; 35(3):1054-62. PubMed ID: 24930484
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
[TBL] [Abstract][Full Text] [Related]
4. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
5. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis.
Kim BS; Seo YS; Kim YS; Lee CH; Lee HA; Um SH; Yoo JJ; Kim SG; Suh SJ; Jung YK; Ahn SH; Han KH; Yim HJ; Kim SU;
J Gastroenterol Hepatol; 2018 Feb; 33(2):503-510. PubMed ID: 28666070
[TBL] [Abstract][Full Text] [Related]
6. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
7. Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Azuma S; Asahina Y; Kakinuma S; Azuma K; Miyoshi M; Inoue E; Tsunoda T; Sato A; Kaneko S; Nagata H; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Tomita M; Nakagawa M; Watanabe M
Dig Dis; 2019; 37(3):247-254. PubMed ID: 30625487
[TBL] [Abstract][Full Text] [Related]
8. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
9. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography.
Masuzaki R; Tateishi R; Yoshida H; Yoshida H; Sato S; Kato N; Kanai F; Sugioka Y; Ikeda H; Shiina S; Kawabe T; Omata M
J Clin Gastroenterol; 2008 Aug; 42(7):839-43. PubMed ID: 18668703
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement.
Cerrito L; Mignini I; Ainora ME; Mosoni C; Gasbarrini A; Zocco MA
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765595
[TBL] [Abstract][Full Text] [Related]
11. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
[TBL] [Abstract][Full Text] [Related]
12. Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation.
Lee YR; Park SY; Kim SU; Jang SY; Tak WY; Kweon YO; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Hur K
J Gastroenterol Hepatol; 2017 May; 32(5):1079-1086. PubMed ID: 27859615
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
[TBL] [Abstract][Full Text] [Related]
14. Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study.
Seo YS; Jang BK; Um SH; Hwang JS; Han KH; Kim SG; Lee KS; Kim SU; Kim YS; Lee JI
Oncotarget; 2017 Dec; 8(68):113213-113224. PubMed ID: 29348900
[TBL] [Abstract][Full Text] [Related]
15. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
16. Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease.
Lee HW; Park SY; Kim SU; Jang JY; Park H; Kim JK; Lee CK; Chon YE; Han KH
PLoS One; 2016; 11(6):e0157358. PubMed ID: 27284700
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B.
Jeon MY; Lee HW; Kim SU; Kim BK; Park JY; Kim DY; Han KH; Ahn SH
Liver Int; 2018 Apr; 38(4):676-686. PubMed ID: 28865176
[TBL] [Abstract][Full Text] [Related]
18. An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia.
Lee HW; Park SY; Lee M; Lee EJ; Lee J; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK
Liver Int; 2020 Jul; 40(7):1736-1743. PubMed ID: 32239602
[TBL] [Abstract][Full Text] [Related]
19. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent.
Wang JH; Hu TH; Chen CH; Hung CH; Yen YH; Chang KC; Lu SN
Kaohsiung J Med Sci; 2019 Nov; 35(11):708-714. PubMed ID: 31430035
[TBL] [Abstract][Full Text] [Related]
20. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY
Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
